|1.||Stamatoyannis, Nikolaos: 1 article (09/2009)|
|2.||Stamatiou, Georgia: 1 article (09/2009)|
|3.||Aidonidis, Isaac: 1 article (09/2009)|
|4.||Molyvdas, Paschalis-Adam: 1 article (09/2009)|
|5.||Lymberi, Maria: 1 article (09/2009)|
|6.||Poyatzi, Aphrodite: 1 article (09/2009)|
|7.||Stowe, David F: 1 article (08/2004)|
|8.||Rhodes, Samhita S: 1 article (08/2004)|
|9.||Riess, Matthias L: 1 article (08/2004)|
|10.||Camara, Amadou K S: 1 article (08/2004)|
11/01/1994 - "However, intracoronary infusion with bimakalim during the 3-min preconditioning period markedly reduced myocardial infarct size to a similar extent as that of ischemic preconditioning (12.2 +/- 1.9%). "
11/01/1994 - "Subsequently, it was observed that either 3 min of LAD occlusion or a 3-min intracoronary infusion with 0.3 micrograms/min of bimakalim did not reduce myocardial infarct size. "
04/01/1994 - "We examined the effect of a new potassium channel opener, bimakalim, on myocardial infarct size (IS) in dogs. "
04/01/1994 - "Reduction in myocardial infarct size by the new potassium channel opener bimakalim."
08/01/1992 - "In pigs with a 3- to 4-week-old myocardial infarction, the vasodilator responses to bimakalim (n = 8) and nicorandil (n = 9) were not affected, but the increases in heart rate and LVdP/dtmax were attenuated compared to the effects in the normal animals.(ABSTRACT TRUNCATED AT 250 WORDS)"
07/01/1999 - "Evidence is provided for protective effects of the K(ATP) opener bimakalim on the human myocardial contractile function in conditions of hypoxia/reoxygenation, at concentrations at which negative inotropism and APD90 shortening are not contributory."
07/01/1999 - "In the short-duration hypoxia protocol, preparations treated with bimakalim showed a dobutamine-induced %DT increase significantly higher (p < 0.001) than in controls and similar to that observed in the absence of hypoxia. "
07/01/1999 - "Treated preparations were exposed to 10 or 100 nM bimakalim, 1 microM glibenclamide, or both before hypoxia. "
06/01/1998 - "Thus, the aim of the present study was to determine the role of adenosine in mediating the cardioprotective effects of PC produced by 5 min of ischemia, hypoxia, or by a 5-min intracoronary (i.c.) infusion of the KATP channel opener bimakalim (1 microgram/min). "
06/01/1998 - "In conclusion (1): PC produced by ischemia or hypoxia results in an increase in interstitial adenosine prior to a prolonged occlusion period; (2) the KATP channel agonist, bimakalim, significantly decreased interstitial adenosine prior to a prolonged occlusion period; (3) ischemic PC, hypoxic PC, and bimakalim pretreatment produced a similar reduction in interstitial adenosine and its breakdown products during the prolonged ischemic period. "
01/01/2004 - "Aim of the study was to evaluate anti-ischemic, hemodynamic and neurohumoral effects of bimakalim, a novel selective K(+)-channel opener, in patients with stable angina pectoris and reproducible ST-segment depression. "
01/01/2004 - "In exercise-induced angina pectoris, administration of bimakalim was neither associated with attenuation of ST-segment depression nor resulted in prolongation of time to 0.1 mV ST-segment depression. "
01/01/2004 - "The results of the present study suggest that bimakalim has a dose-dependent vasodilatatory activity but exerts no anti-ischemic benefits in patients with exercise-induced angina pectoris due to coronary artery disease."
01/01/2004 - "Lack of anti-ischemic efficacy of the potassium channel opener bimakalim in patients with stable angina pectoris."
03/01/2000 - "Using right heart catheterization and exercise tolerance tests, we investigated the hemodynamic, antiischemic and neurohumoral effects of bimakalim and tedisamil in patients with angiographically proven coronary artery disease, stable angina pectoris and reproducible ST segment depression during exercise. "
07/01/1993 - "In a model of irreversible ischaemia/reperfusion injury (120 min of ischaemia and 30 min of reperfusion) pre-treatment with equihypotensive doses of nicorandil and bimakalim produced marked reductions in myocardial infarct size. "
07/01/1993 - "These results indicate that nicorandil, aprikalim, and bimakalim are protective in two experimental models of ischaemia/reperfusion injury. "
08/01/1994 - "Similarly, in a model of irreversible ischaemia/reperfusion injury (90 min of coronary artery occlusion followed by 5 h of reperfusion), intravenous infusion of bimakalim at a dose which reduced aortic blood pressure approximately 15-20 mmHg or infusion of aprikalim at a non-hypotensive dose throughout the entire experiment produced a significant reduction in myocardial infarct size. "
08/01/1994 - "In a model of reversible ischaemia/reperfusion injury, administration of bimakalim as an intravenous bolus prior to ischaemia or administration of a non-hypotensive dose of aprikalim as a constant intravenous infusion resulted in a reduction in reperfusion contractile dysfunction (myocardial 'stunning') produced by a single 15-min coronary artery occlusion. "
07/01/1993 - "The effect of three potassium channel openers, nicorandil, aprikalim, and bimakalim, on experimental myocardial ischaemia/reperfusion injury was examined in barbital-anaesthetized dogs. "
11/01/1994 - "PC was elicited by a single period of 10 min left anterior descending coronary artery (LADCA) occlusion followed by 15 min of reperfusion before the LADCA was reoccluded for 60 min. Instead of PC, bimakalim infusion was started 15 min before the 60 min LADCA occlusion (TCO) and stopped with the onset of ischemia. "
11/01/1994 - "In addition, it was observed that bimakalim markedly accelerated the ischemia-induced shortening of the action potential during preconditioning. "
04/01/1994 - "Subsequently, we found that the two higher doses of bimakalim (0.3 and 3.0 micrograms/min) markedly accelerated yet the 0.1-microgram/min dose of bimakalim did not significantly affect the ischemia-related shortening of the action potential during the initial 5 minutes of occlusion. "
04/01/1994 - "A second aim was to test the possibility that bimakalim mediates its cardioprotective effects by accelerating the rate of myocyte action potential shortening during early ischemia. "
08/01/2004 - "Each drug except bimakalim increased VR(max) and VR(min) before ischemia; after ischemia, only BDM and nifedipine increased VR(max) and VR(min). "
|1.||Potassium Channels (Potassium Channel)
|2.||Adenosine Triphosphate (ATP)
|4.||Nicorandil (SG 75)